1. Home
  2. MRCY vs TVTX Comparison

MRCY vs TVTX Comparison

Compare MRCY & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercury Systems Inc

MRCY

Mercury Systems Inc

HOLD

Current Price

$80.76

Market Cap

5.0B

Sector

N/A

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

N/A

Current Price

$66.22

Market Cap

5.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MRCY
TVTX
Founded
1981
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.3B
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
MRCY
TVTX
Price
$80.76
$66.22
Analyst Decision
Buy
Strong Buy
Analyst Count
8
13
Target Price
$80.00
$40.62
AVG Volume (30 Days)
774.5K
1.2M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
23.08
92.89
EPS
N/A
N/A
Revenue
$983,622,000.00
N/A
Revenue This Year
$6.59
$44.76
Revenue Next Year
$9.56
$35.51
P/E Ratio
N/A
N/A
Revenue Growth
7.85
N/A
52 Week Low
$65.04
$22.06
52 Week High
$128.45
$68.03

Technical Indicators

Market Signals
Indicator
MRCY
TVTX
Relative Strength Index (RSI) 31.78 59.71
Support Level $71.60 $53.76
Resistance Level $88.06 N/A
Average True Range (ATR) 3.99 2.02
MACD -0.96 -0.31
Stochastic Oscillator 4.25 59.79

Price Performance

Historical Comparison
MRCY
TVTX

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: